Difference between revisions of "Talk:MitoFit news"
From Bioblast
| Line 2: | Line 2: | ||
=== Ready === | === Ready === | ||
*'''014'''. 2015-09- | *'''014'''. 2015-09-03: Defining mt-hypoxia with the [[NextGen-O2k]]: » [[Harrison 2015 J Appl Physiol]] | ||
:: Open Innovation: the NextGen-O2k is not yet in series production, but some special innovations are now available: [[O2k-Titration_Set |'''OROBOROS racks''']] make experiments with SUIT protocols more convenient. | |||
Revision as of 17:34, 1 September 2015
MitoFit news in preparation by OROBOROS
Ready
- 014. 2015-09-03: Defining mt-hypoxia with the NextGen-O2k: » Harrison 2015 J Appl Physiol
- Open Innovation: the NextGen-O2k is not yet in series production, but some special innovations are now available: OROBOROS racks make experiments with SUIT protocols more convenient.
In preparation
- ... Thyfault JP (with question on Copenhagen)
- 01#. 2015-07-##: Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. » Bowen 2015 Eur J Heart Fail
- 01#. 2015-07-##: » Mortensen 2015 Adv Exp Med Biol
- 01#. 2015-07-##: » Ludzki 2015 Diabetes
- 01#. 2015-07-##: » Conner 2015 FASEB J
- 01#. 2015-07-##: » Chausse 2015 PLoS One
- 01#. 2015-07-##: » Ramos-Filho 2015 PLoS One
- 01#. 2015-07-##: » Spinazzi 2014 Neuropathol Appl Neurobiol (suggestions by Georg)
